

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)**Sunitinib for the treatment of gastrointestinal stromal tumours****Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)**

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Sunitinib for the treatment of gastrointestinal stromal tumours

Issue date: August 2008

1.	<i>GIST Support UK is a subgroup of Sarcoma UK and may develop as an independent body during 2008. We would like to see it identified separately in the matrix, although Sarcoma UK and GIST Support UK will collaborate on a single patient input to any appraisal</i>	Sarcoma UK	Not Added	<i>Until GIST Support UK becomes an independent body, the organisation does not fit the inclusion criteria therefore GIST Support UK have not been added to the matrix.</i>
----	---	------------	-----------	---

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Sunitinib for the treatment of gastrointestinal stromal tumours

Issue date: August 2008